<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html xmlns:n1="urn:hl7-org:v3" xmlns:in="urn:lantana-com:inline-variable-data" xmlns:sdtc="urn:hl7-org:sdtc"><head>
<meta charset="utf-8"><!-- Do NOT edit this HTML directly: it was generated via an XSLT transformation from a CDA Release 2 XML document. --><title>[REDACTED] Progress Note</title><style type="text/css">
body {
  color: #003366;
  background-color: #FFFFFF;
  font-family: Verdana, Tahoma, sans-serif;
  font-size: 14px;
}

a {
  color: #003366;
  background-color: #FFFFFF;
}

h1 {
  font-size: 20px;
  font-weight: bold;
}

h2 {
  font-size: 18px;
  font-weight: bold;
}

h3 {
  font-size: 14px;
  font-weight: bold;
}

h4 {
  font-size: 14px;
  font-weight: bold;
}


table {
  width: 100%;
}

th {
  background-color: #ffd700;
}

td {
  padding: 0.1cm 0.2cm;
  vertical-align: top;
  background-color: #ffffcc;
}

.h1center {
  font-size: 20px;
  font-weight: bold;
  text-align: center;
  width: 80%;
}

.header_table{
  border: 1pt inset #00008b;
}

.td_label{
  font-weight: bold;
  color: white;
}

.content_span{
 font-family: Verdana, Tahoma, sans-serif;
 display: inline;
 white-space: pre-line;
}

.td_header_role_name{
  width: 20%;
  background-color: #3399ff;
}

.td_header_role_value{
  width: 80%;
  background-color: #ccccff;
}

.Bold{
  font-weight: bold;
}

.Italics{
  font-style: italic;
}

.Underline{
  text-decoration:underline;
}

.internal_format
{
	list-style: none;
	list-style-position:outside;
	margin:0;
	padding:0;
	border:0;
	border-collapse: collapse;
}
          </style></head><body>
<h2><a name="toc">Table of Contents</a></h2><ul><li><a href="#id1">Assessment</a></li><li><a href="#id2">Allergies and Adverse Reactions</a></li><li><a href="#id3">Plan</a></li><li><a href="#id4">Reason for Visit</a></li><li><a href="#id5">Encounters</a></li><li><a href="#id6">Immunizations</a></li><li><a href="#id7">Diagnostic Results</a></li><li><a href="#id8">Medications</a></li><li><a href="#id9">Problems</a></li><li><a href="#id10">Vital Signs</a></li><li><a href="#id11">Notes Section</a></li></ul><hr align="left" color="teal" size="2"/><h3><a name="id1" href="#toc">Assessment</a></h3><div>See Clinical Notes section</div><h3><a name="id2" href="#toc">Allergies and Adverse Reactions</a></h3><div><table>
    <thead>
        <tr>
                            <th>Medication/Group Name</th>
                <th>Reaction</th>
                <th>Severity</th>
                <th>Date</th>
        </tr>
    </thead>
    <tbody>
                <tr ID="AlertOBS-1000">
                            <td>Tuna fish (substance)</td>
                            <td/>
                            <td/>
                            <td>[REDACTED]</td>
                </tr>
                <tr ID="AlertOBS-1001">
                            <td>sulfite</td>
                            <td/>
                            <td/>
                            <td>[REDACTED]</td>
                </tr>
    </tbody>
</table>
</div><h3><a name="id3" href="#toc">Plan</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Type</th>
				<th>Value</th>
		</tr>
	</thead>
	<tbody>
				<tr ID="CarePlanRef-1002">
						<td>[REDACTED]</td>
						<td>APPOINTMENT</td>
						<td>FOLLOW UP</td>
				</tr>
				<tr ID="CarePlanRef-1003">
						<td>[REDACTED]</td>
						<td>APPOINTMENT</td>
						<td>FOLLOW UP</td>
				</tr>
				<tr ID="CarePlanRef-1004">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>Vitamin D, 25-hydroxy</td>
				</tr>
				<tr ID="CarePlanRef-1005">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>CEA</td>
				</tr>
				<tr ID="CarePlanRef-1006">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>Ferritin</td>
				</tr>
				<tr ID="CarePlanRef-1007">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>CA 27-29</td>
				</tr>
				<tr ID="CarePlanRef-1008">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>Vitamin B12 and Folate panel</td>
				</tr>
				<tr ID="CarePlanRef-1009">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>C-reactive protein (CRP), cardiac</td>
				</tr>
				<tr ID="CarePlanRef-1010">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>CA 125</td>
				</tr>
				<tr ID="CarePlanRef-1011">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>Iron, TIBC, %SAT</td>
				</tr>
				<tr ID="CarePlanRef-1012">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>Hepatic function panel</td>
				</tr>
				<tr ID="CarePlanRef-1013">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>Renal function panel</td>
				</tr>
	</tbody>
</table>
</div><h3><a name="id4" href="#toc">Reason for Visit</a></h3><div>EXTENDED FOLLOW UP</div><h3><a name="id5" href="#toc">Encounters</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Name</th>
		</tr>
	</thead>
	<tbody>
					<tr ID="EncounterDiagnosisRef-1014">
							<td>[REDACTED]</td>
							<td>Breast cancer, female</td>						
					</tr>
					<tr ID="EncounterDiagnosisRef-1015">
							<td>[REDACTED]</td>
							<td>Breast cancer, female</td>						
					</tr>
					<tr ID="EncounterDiagnosisRef-1016">
							<td>[REDACTED]</td>
							<td>Estrogen receptor positive status [ER+] </td>						
					</tr>
					<tr ID="EncounterDiagnosisRef-1017">
							<td>[REDACTED]</td>
							<td>Osteoporosis</td>						
					</tr>
					<tr ID="EncounterDiagnosisRef-1018">
							<td>[REDACTED]</td>
							<td>Postmastectomy lymphedema syndrome (disorder)</td>						
					</tr>
					<tr ID="EncounterDiagnosisRef-1019">
							<td>[REDACTED]</td>
							<td>Vitamin D deficiency (disorder)</td>						
					</tr>
	</tbody>
</table>
</div><h3><a name="id6" href="#toc">Immunizations</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Name</th>
				<th>Route</th>
				<th>Dose</th>
				<th>Instructions</th>
				<th>Refusal Reason</th>
				<th>Status</th>
		</tr>
	</thead>
	<tbody>
				<tr><td colspan="7">No data for this encounter</td></tr>
	</tbody>
</table>
</div><h3><a name="id7" href="#toc">Diagnostic Results</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Type</th>
				<th>Test</th>
				<th>Units</th>
				<th>Lower Limit</th>
				<th>Upper Limit</th>
				<th>Result</th>
				<th>Flag</th>
				<th>Comments</th>
				<th>Status</th>
				<th>Ordered By</th>
				<th>Specimen Source</th>
				<th>Lab Address</th>
		</tr>
	</thead>
	<tbody>
			<tr><td colspan="13">NONE</td></tr>
	</tbody>
</table>
</div><h3><a name="id8" href="#toc">Medications</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Name</th>
				<th>Route</th>
				<th>Dose</th>
				<th>Frequency</th>
				<th>Instructions</th>
				<th>Start Date</th>
				<th>End Date</th>
				<th>Status</th>
		</tr>
	</thead>
	<tbody>
					<tr ID="MedicationOBS-1020">
							<td/>
							<td>Umeclidinium-Vilanterol Inhaler 62.5 mcg-25 mcg/actuation </td>
							<td/>
							<td> </td>
							<td/>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1021">
							<td/>
							<td>Pravastatin Sodium Oral </td>
							<td/>
							<td> </td>
							<td/>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1022">
							<td/>
							<td>Albuterol HFA Inhaler 90 mcg/actuation </td>
							<td/>
							<td> </td>
							<td/>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1023">
							<td/>
							<td>Fluticasone Nasal Spray 50 mcg/actuation </td>
							<td/>
							<td> </td>
							<td/>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1024">
							<td/>
							<td>bupropion Oral SR 12 hr Tab </td>
							<td/>
							<td> </td>
							<td/>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1025">
							<td/>
							<td>Cholecalciferol Oral </td>
							<td/>
							<td> </td>
							<td/>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1026">
							<td/>
							<td>Levothyroxine Oral </td>
							<td/>
							<td> </td>
							<td/>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1027">
							<td>[REDACTED]</td>
							<td>Letrozole Oral </td>
							<td>orally</td>
							<td>1.0 capsule</td>
							<td>daily</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1028">
							<td>[REDACTED]</td>
							<td>100 ML zoledronic acid 0.05 MG/ML Injection [Reclast] </td>
							<td>intravenously</td>
							<td>5.0 mg</td>
							<td>once</td>
							<td>Flush line after infusion with 10 mL NS.</td>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1029">
							<td>[REDACTED]</td>
							<td>alendronic acid 70 MG Oral Tablet </td>
							<td>orally</td>
							<td>1.0 tablet</td>
							<td>every week</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1030">
							<td>[REDACTED]</td>
							<td>Letrozole Oral </td>
							<td>orally</td>
							<td>1.0 capsule</td>
							<td>daily</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1031">
							<td>[REDACTED]</td>
							<td>alendronic acid 70 MG Oral Tablet </td>
							<td>orally</td>
							<td>1.0 tablet</td>
							<td>every week</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1032">
							<td>[REDACTED]</td>
							<td>Letrozole Oral </td>
							<td>orally</td>
							<td>1.0 capsule</td>
							<td>daily</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1033">
							<td>[REDACTED]</td>
							<td>Letrozole Oral </td>
							<td>orally</td>
							<td>1.0 capsule</td>
							<td>daily</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1034">
							<td>[REDACTED]</td>
							<td>alendronic acid 70 MG Oral Tablet </td>
							<td>orally</td>
							<td>1.0 tablet</td>
							<td>every week</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1035">
							<td>[REDACTED]</td>
							<td>alendronic acid 70 MG Oral Tablet </td>
							<td>orally</td>
							<td>1.0 tablet</td>
							<td>every week</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1036">
							<td>[REDACTED]</td>
							<td>hydrochlorothiazide 12.5 MG / valsartan 80 MG Oral Tablet </td>
							<td>orally</td>
							<td>1.0 tab</td>
							<td>daily</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1037">
							<td>[REDACTED]</td>
							<td>Letrozole Oral </td>
							<td>orally</td>
							<td>1.0 capsule</td>
							<td>daily</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1038">
							<td>[REDACTED]</td>
							<td>Letrozole Oral </td>
							<td>orally</td>
							<td>1.0 capsule</td>
							<td>daily</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1039">
							<td>[REDACTED]</td>
							<td>Letrozole Oral </td>
							<td>orally</td>
							<td>1.0 capsule</td>
							<td>daily</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1040">
							<td>[REDACTED]</td>
							<td>Letrozole Oral </td>
							<td>orally</td>
							<td>1.0 capsule</td>
							<td>daily</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
	</tbody>
</table>
</div><h3><a name="id9" href="#toc">Problems</a></h3><div><table>
	<thead>
		<tr>
							<th>Diagnosis</th>
				<th>Status</th>
				<th>Date of Diagnosis</th>
		</tr>
	</thead>
	<tbody>
				<tr ID="ProblemOBS-1041">
						<td>BMI 30+ - obesity</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1042">
						<td>UTI</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1043">
						<td>Breast cancer, female</td>
						<td>Active</td>
						<td>[REDACTED]</td>
				</tr>
				<tr ID="ProblemOBS-1044">
						<td>Estrogen receptor positive status [ER+] </td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1045">
						<td>Breast cancer, female</td>
						<td>Active</td>
						<td>[REDACTED]</td>
				</tr>
				<tr ID="ProblemOBS-1046">
						<td>High cholesterol</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1047">
						<td>Lymphedema (disorder)</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1048">
						<td>Postmastectomy lymphedema syndrome (disorder)</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1049">
						<td>Essential HTN</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1050">
						<td>Vitamin D deficiency (disorder)</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1051">
						<td>Estrogen receptor positive status [ER+] </td>
						<td>Active</td>
						<td>[REDACTED]</td>
				</tr>
				<tr ID="ProblemOBS-1052">
						<td>Osteoporosis</td>
						<td>Active</td>
						<td/>
				</tr>
	</tbody>
</table>
</div><h3><a name="id10" href="#toc">Vital Signs</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Type</th>
				<th>Value</th>
		</tr>
	</thead>
	<tbody>
				<tr ID="VitalSignsRef-1053">
						<td>[REDACTED]</td>
						<td>
							Body Temperature
							
						</td>
						<td>97.50</td>
				</tr>
				<tr ID="VitalSignsRef-1054">
						<td>[REDACTED]</td>
						<td>
							Heart Beat
							
						</td>
						<td>54.00</td>
				</tr>
				<tr ID="VitalSignsRef-1055">
						<td>[REDACTED]</td>
						<td>
							Respiratory Rate
							
						</td>
						<td>16.00</td>
				</tr>
				<tr ID="VitalSignsRef-1056">
						<td>[REDACTED]</td>
						<td>
							Oxygen Saturation
							
						</td>
						<td>94.00</td>
				</tr>
				<tr ID="VitalSignsRef-1057">
						<td>[REDACTED]</td>
						<td>
							BSA
							
						</td>
						<td>1.90</td>
				</tr>
				<tr ID="VitalSignsRef-1058">
						<td>[REDACTED]</td>
						<td>
							Pain Scale
							
						</td>
						<td>0.00</td>
				</tr>
				<tr ID="VitalSignsRef-1059">
						<td>[REDACTED]</td>
						<td>
							Weight
							
						</td>
						<td>197.00</td>
				</tr>
				<tr ID="VitalSignsRef-1060">
						<td>[REDACTED]</td>
						<td>
							Height
							
						</td>
						<td>62.00</td>
				</tr>
				<tr ID="VitalSignsRef-1061">
						<td>[REDACTED]</td>
						<td>
							BMI
							
						</td>
						<td>36.03</td>
				</tr>
				<tr ID="VitalSignsRef-1062">
						<td>[REDACTED]</td>
						<td>
							Intravascular Systolic
							
						</td>
						<td>122</td>
				</tr>
				<tr ID="VitalSignsRef-1063">
						<td>[REDACTED]</td>
						<td>
							Intravascular Diastolic
							
						</td>
						<td>60</td>
				</tr>
	</tbody>
</table>
</div><h3><a name="id11" href="#toc">Notes Section</a></h3><div>	<ul><li>
		        Follow-Up: 
		        <p>
		        		

<br/>[REDACTED][REDACTED]/>Suite 301<br/>[REDACTED][REDACTED]

<br/>
<br/>Phone: [REDACTED] Fax: [REDACTED]


<br/>


<br/>Patient Name: [REDACTED]

<br/>Date of Birth: [REDACTED]

<br/>Medical Record #: [REDACTED]

<br/>Attending Physician: [REDACTED], MD

<br/>Location: [REDACTED]

<br/>Referring Physician: [REDACTED], NPFP

<br/>


<br/>Follow-Up

<br/>Date of Visit: [REDACTED]

<br/>Reason for Visit<br/>Ongoing f/up b/l Breast cancer: <br/>L-Breast pT2 N0(i+)/ stage IIa vs IIb; <br/>R-Breast: pT2 N0 / stage IIa<br/>So far [REDACTED]<br/>She recovered from recent hospitalzation for pneumonia<br/>- Review of DEXA scan: [REDACTED]: osteporosis<br/>- CT chest: [REDACTED]: No focal pulmonary consolidation. Moderate emphysematous change with<br/>pleural parenchymal scarring.<br/>- Continues on letrozole<br/>

<br/>History of Present Illness

<br/>This is a pleasant [REDACTED] female diagnosed with b/l breast cancer. She found a palpable mass in [REDACTED] and [REDACTED] the diagnostic bilateral digital breast tomosynthesis mammogram disclosed: <br/>i- dominant mass solid by ultrasound L-breast superior lateral quadrant 2.5 cm highly suspicious for malignancy. <br/>ii- Architectural distortion 12 o'clock position middle third right breast highly suspicious for malignancy.  Subsequently had bilateral breast biopsy [REDACTED], pathology disclosed <br/>R-breast: Invasive lobular carcinoma, grade 1/3, ER/PR+, Her2 neu negative.  <br/>L-breast: Invasive carcinoma with mixed ductal and lobular features, grade 1/3, ER/PR+, Her2 neu negative.<br/>[REDACTED] - CAT scan of the chest, abdomen and pelvis showed 2.6 cm irregular mass in the left breast consistent with primary breast malignancy.  There was no evidence of metastatic disease in the chest, abdomen and pelvis.  Bilateral renal cysts.<br/>She completed 2 cycles of Verzenio/Abemaciclib +Letrozole in neoadjuvant setting, followed by b/l radical mastectomy [REDACTED] without reconstruction.<br/>Pathology showed:<br/>Left breast: well differentiated invasive lobular carcinoma, ER/PR+, Her2 negative; pT2 pN0(i+)<br/>Right breast: moderately differentiated invasive lobular carcinoma, ER/PR+, Her2 negative; pT2 pN0<br/>[REDACTED]: Oncotype RS 11<br/>[REDACTED]: Breast Cancer Index shows benefit of extended endocrine therapy.<br/>She  continuous adjuvant Letrozole.<br/>Interim Hx:<br/>[REDACTED] - She continues to complain of worsening lymphedema left chest wall, initially required repeated drainage by the surgeon continues follow up with [REDACTED]. Gaining weight but overall feeling well. Continues to have some menopausal symptoms including hair thinning while on Letrozole, but tolerating well otherwise. <br/>She had recent hospitalization for bacterial pneumonia, still recovering followed by [REDACTED] (Pulmonology).<br/>

<br/>Medical History<br/>-. Breast cancer, L breast pT2 N0(i+) - stage IIa vs IIb<br/>-. Breast cancer, R female pT2 N0 - stage IIa<br/>-. Estrogen receptor positive status [ER+]<br/>-. Postmastectomy lymphedema syndrome <br/>-. Vitamin D deficiency <br/>-. Essential HTN<br/>-. High cholesterol<br/>-. UTI

<br/>


<br/>Surgical History<br/>Radical Mastectomy extended bilateral   [REDACTED]

<br/>


<br/>Medications<br/> Anoro Ellipta (Umeclidinium-Vilanterol Inhaler 62.5 mcg-25 mcg/actuation) 62.5-25 mcg/actuation blister with device, <br/>Alendronate Oral (Weekly) 70 mg tablet 
1 tablet orally every week.   take 1 tablet by mouth once weekly. sit upright for 60 minutes after
, <br/>Fluticasone Nasal Spray 50 mcg/actuation 50 mcg/actuation spray,suspension, <br/>Valsartan-Hydrochlorothiazide Oral 80 mg-12.5 mg 80-12.5 mg tablet 
1 tab orally daily. , <br/>Albuterol HFA Inhaler 90 mcg/actuation 90 mcg/actuation HFA aerosol inhaler, <br/>Vitamin D (Cholecalciferol Oral) 1,250 mcg (50,000 unit) capsule, <br/>Letrozole Oral 2.5 mg capsule 
1 capsule orally daily. , <br/>Bupropion (SR) Oral ER Tab, <br/>Levothyroxine Oral 150 mcg tablet, <br/>Pravastatin Sodium Oral 40 mg tablet

<br/>

<br/>Smoking History<br/>


<br/>Smoking Tobacco : Current every day smoker; <br/>Smokeless Tobacco : none found; <br/>Vaping : none found

<br/>


<br/>Social History

<br/>

<br/>Family History<br/>    

<br/>


<br/>Allergies<br/> Tuna fish (substance)<br/>sulfite

<br/>


<br/>Review of Systems

<br/>Constitutional: Denies fever, weight loss, fatigue<br/>Eyes: Denies visual changes<br/>ENT/Mouth: Denies hearing problems, oral problems<br/>Cardiovascular: Denies chest pain, palpitations<br/>Respiratory: Denies shortness of breath, cough<br/>Breast: Denies pain, masses, discharge<br/>Gastrointestinal: Denies abdominal pain, nausea, vomiting, constipation, diarrhea<br/>Genitourinary: Denies burning, pain on urination, blood in urine, incontinence<br/>Gynecological: Denies vaginal discharge, abnormal vaginal bleeding<br/>Musculoskeletal: Denies muscle pain, bone pain, joint pain<br/>Skin: Denies rashes, itchiness, ulcers<br/>Neurologic: Denies headaches, dizziness, confusion, seizures, weakness or numbness <br/>Psychiatric: Denies depression, anxiety<br/>Hematologic/Lymphatic: Denies other bleeding, bruising, swollen lymph nodes

<br/>


<br/>Physical Examination

<br/>Blood pressure: 122/60, R arm, Regular, Pulse: 54, Temperature: 97.5 F, Respirations: 16, O2 sat: 94%, At Rest, Room Air, Pain Scale: 0, Height: 62 in, Weight: 197 lb, BSA: 1.9, BMI: 36.03 kg/m2

<br/>General:  Alert &amp; oriented, no acute distress<br/>Skin: Normal<br/>HEENT:  Pupils equal, round. Oral cavity, oropharynx clear<br/>Neck:  Supple, no mass<br/>Breast:  healed b/l mastectomy. left side chest swelling, no erythema, no lymphadenopathy<br/>Lungs: Clear to auscultation, bilaterally<br/>Heart: Regular rate and rhythm, no murmurs, rubs or gallops<br/>Back: Nontender<br/>Abdomen: Soft, nontender, nondistended, no masses palpable, no hepatosplenomegaly, normal bowel sounds<br/>Genitourinary: Deferred<br/>Extremities: No clubbing, cyanosis, or edema<br/>

<br/>


<br/>Laboratory<br/>
<br/>CBC<br/>([REDACTED]) WBC x 10^3/uL : 6.2; RBC x 10^6/uL : 4.47; HGB g/dL : 13.7; HCT % : 40.9; MCV fL : 91.5; MCH pg : 30.6; MCHC g/dL : 33.5; RDW % : 13.0; PLT x 10^3/uL : 233; MPV fL : 10.3; Neu % : 56.9; LY % : 29.7; MO % : 10.0; EO % : 2.9; BA % : 0.5; NEU #, cells/uL : 3528; LY #, cells/uL : 1841; MO #, cells/uL : 620; EO #, cells/uL : 180; BA #, cells/uL : 31

<br/>
<br/>Manual Differential<br/>([REDACTED]) NRBC, #/100 wbc : DNR; NRBC, absolute, cells/uL (M) cells/uL : DNR; Band % : DNR; Promyelocyte % : DNR; Bands, absolute, cells/uL : DNR; Promyelocyte, absolute, cells/uL : DNR

<br/>CMP<br/>([REDACTED]) Glucose mg/dL : 92; BUN mg/dL : 31 (H); Creatinine mg/dL : 0.92; BUN/Creatinine ratio : 34 (H); Sodium mmol/L : 138; Potassium mmol/L : 4.5; Chloride mmol/L : 105; CO2 mmol/L : 27; Calcium mg/dL : 9.5; Albumin g/dL : 3.8; Total protein g/dL : 7.0; Globulin g/dL : 3.2; A/G ratio : 1.2; Bilirubin, total mg/dL : 0.9; Bilirubin, direct mg/dL : 0.2; Bilirubin, indirect mg/dL : 0.7; Alkaline phosphatase U/L : 90; AST/SGOT U/L : 20; ALT/SGPT U/L : 22; Phosphorus mg/dL : 3.3; Vitamin D, 25-hydroxy ng/mL : 66

<br/>Tumor Markers<br/>([REDACTED]) CA 27-29 U/mL : 31

<br/>Anemia Labs<br/>([REDACTED]) Iron / FE ug/dL : 150; TIBC ug/dL : 308; Ferritin ng/mL : 179; Vitamin B12 pg/mL : 286; Folate, serum ng/mL : 9.1

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>Other<br/>([REDACTED]) CBC Comments : DNR; ABSOLUTE BLASTS : DNR; ABSOLUTE METAMYELOCYTES : DNR; ABSOLUTE MYELOCYTES : DNR; BLASTS : DNR; METAMYELOCYTES : DNR; MYELOCYTES : DNR; REACTIVE LYMPHOCYTES : DNR; Enhanced PDF Report ZL908869B-1 : See attached; Clinical PDF Report EN406296Y-1 : See attached; EGFR : 65; % SATURATION : 49 (H)


<br/>



<br/>Radiology<br/>
<br/>


<br/>Pathology<br/> 
[REDACTED] - b/l mastectomy

<br/>

<br/>Left breast mastectomy: Invasive ductal carcinoma.  Well-differentiated 1/3.  

<br/>Tumor measures 3.4 cm in greatest dimension.  Ductal carcinoma in situ 1% of the tumor volume.  Low nuclear grade.  Lymphovascular invasion is not identified.  

<br/>Tumor is 2 mm from the deep margin, all other margins are over 1 cm.  

<br/>ER(+)/51-90%, PR(+)/51-90%, HER-2 0, by IHC.

<br/>Number of positive lymph nodes N1(+) out of 3.  

<br/>Size of largest metastatic focus: Less than &lt;1 mm, isolated tumor cells only. 

<br/>Extranodal tumor deposit identified: 0.7 cm.  

<br/>AJCC pTNM classification: pT2 pN0(i+); [concern that the staging is not correct because Micro-metastases are defined as clusters of cancer cells that are between 0.2 millimeters and 2 millimeters (mm) in diameter. Any smaller clusters are called isolated tumor cells); therefore the correct definition is pN1 not pN0(i+).]


<br/>As far as the extranodal extention this should be reported to the surgeon

<br/>


<br/>Right breast: Invasive lobular carcinoma, measuring 2.2 cm in greatest dimension.  Nottingham histologic grade 6/9, moderately differentiated.  

<br/>Size of invasive tumor 2.2 cm.  0 out of 3 positive lymph nodes.  

<br/>Lymphovascular invasion present.  

<br/>ER(+)/51-90%, PR(+)/51-90%, HER-2 0, by IHC.  

<br/>AJCC pTNM: pT2 pN0.
<br/>
[REDACTED] - b/l need biopsy<br/>
<br/>
<br/>Right breast: Invasive lobular carcinoma,  grade 1 out of 3.  Greatest dimension of largest invasive focus 0.9 cm.  Ductal carcinoma in situ, lobular carcinoma in situ not identified.  Lymphovascular invasion not identified.  Microcalcifications are present.  Estrogen receptor strongly positive, progesterone receptor strongly positive, HER-2 no overexpression.

<br/>


<br/>Left breast: Invasive carcinoma with mixed ductal and lobular features, histologic grade 1 out of 3.  Greatest dimension of largest invasive focus 1.1 cm at least.  Ductal carcinoma in situ and lobular carcinoma in situ not identified.  Lymphovascular invasion and microcalcifications not identified.  Estrogen receptor strongly +, 51 to 90%.  HER-2 no overexpression.
<br/>
<br/>Impression/Discussion<br/>This is a pleasant [REDACTED] female patient diagnosed with bilateral breast cancer. Invasive lobular carcinoma s/p 2 cycles of neoadjuvant Verzenio/Abemaciclib +Letrozole followed by b/l radical mastectomy without reconstruction.<br/>1.- Pathology Bilateral breast carcinoma s/p bilateral mastectomy staged as:<br/>L-breast: pT2pN0(i+); stage IIa vs IIb since ER(+)/51-90%, PR(+)/51-90%, HER-2 0, by IHC<br/>(the difference between isolated tumor cells (ITCs) and micrometastases, is that the former is &lt; 0.2 mm while the latter is between 0.2-2.0 mm; this tumor is at 1 mm which qualifies <br/>R-breast: pT2 N0 M0 &gt;&gt; stage IIa<br/>2.-  Bilateral chest wall lymphedema L&gt;R, persistent in spite of 4 draining procedures.<br/>She will discuss with [REDACTED] at her upcoming visit<br/>3.-  stable condition and tumor markers normal. She wil;l continue lwetrozole and we will continue monitoring<br/>PS ECOG scale 0<br/>Plan/Recommendations<br/>.- Continue [REDACTED]<br/>.- Repeat labs prior to next visit: CBC, CMP, CA 27.29, Vit B12, folate, Vit D, ferritin, iron<br/>.- Continue follow up with [REDACTED]<br/>.- Continue follow up with [REDACTED] (Pulmonology)<br/>.- Continue follow up with PCP and continue routine screening as per national guidelines.<br/>.- Gradually improve physical health<br/>.- RTC [REDACTED]<br/>

<br/>Diagnosis<br/>


<br/><ul/>Breast cancer, L breast pT2 N0(i+) - stage IIa vs IIb<br/>Breast cancer, R female pT2 N0 - stage IIa<br/>Essential HTN<br/>Postmastectomy lymphedema syndrome (disorder)<br/>UTI<br/>Vitamin D deficiency (disorder)<br/>Estrogen receptor positive status [ER+]<br/>High cholesterol<br/>Lymphedema (disorder)<br/>

<br/>CC<br/>[REDACTED] M.D.<br/>[REDACTED] (Referring) 

<br/>


<br/>Signature<br/>Note created by [REDACTED] MD, Physician,    
<br/>Electronically signed by [REDACTED] MD [REDACTED] 03:20 AM PDT 
		        </p>
		      </li></ul>
</div><br/><br/>
</body></html>